AU4105985A - Implantable formulations of regulatory peptides with controlled release - Google Patents

Implantable formulations of regulatory peptides with controlled release

Info

Publication number
AU4105985A
AU4105985A AU41059/85A AU4105985A AU4105985A AU 4105985 A AU4105985 A AU 4105985A AU 41059/85 A AU41059/85 A AU 41059/85A AU 4105985 A AU4105985 A AU 4105985A AU 4105985 A AU4105985 A AU 4105985A
Authority
AU
Australia
Prior art keywords
zein
active compound
release
implant
buserelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41059/85A
Other languages
English (en)
Inventor
Jurgen Kurt Sandow
Heinz-Rudiger Seidel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU4105985A publication Critical patent/AU4105985A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41059/85A 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release Abandoned AU4105985A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3413608 1984-04-11
DE19843413608 DE3413608A1 (de) 1984-04-11 1984-04-11 Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
AU4105985A true AU4105985A (en) 1985-10-17

Family

ID=6233259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41059/85A Abandoned AU4105985A (en) 1984-04-11 1985-04-10 Implantable formulations of regulatory peptides with controlled release

Country Status (12)

Country Link
EP (1) EP0158277A3 (enExample)
JP (1) JPS60228411A (enExample)
KR (1) KR850007559A (enExample)
AU (1) AU4105985A (enExample)
DE (1) DE3413608A1 (enExample)
DK (1) DK162385A (enExample)
ES (1) ES8607732A1 (enExample)
GR (1) GR850905B (enExample)
HU (1) HUT40760A (enExample)
IL (1) IL74848A0 (enExample)
PT (1) PT80252B (enExample)
ZA (1) ZA852639B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
AU2902289A (en) * 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
AU692794B2 (en) 1993-08-30 1998-06-18 Baylor College Of Medicine Senescent cell-derived inhibitors of DNA synthesis
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
NZ552298A (en) 2004-05-23 2011-04-29 Gerard M Housey Method for identifying inhibitors or activators of a theramutein by comparing the phenoresponse of cells exposed to a test compound
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
ATE480267T1 (de) * 2006-01-05 2010-09-15 Med Inst Inc Zein-beschichtete medizinische vorrichtung
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
EP3127549B1 (en) 2007-06-22 2019-12-18 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
WO2009067431A2 (en) 2007-11-20 2009-05-28 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN101669899B (zh) * 2009-09-29 2011-02-02 河北科技大学 玉米蛋白为主要骨架材料或基质的缓释埋植剂及其用途
EP3366695B1 (en) 2009-12-17 2021-07-07 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
CN101843577A (zh) * 2010-04-08 2010-09-29 安徽中医学院 以玉米醇溶蛋白为骨架材料的包衣植入剂及制备方法
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
EP3560509B1 (en) 2011-12-22 2024-01-31 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN115551594A (zh) 2019-10-24 2022-12-30 米诺陶治疗公司 经细胞因子修饰的嵌合抗体及其使用方法
US20250197525A1 (en) 2021-04-28 2025-06-19 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE184774C (enExample) *
US2895880A (en) * 1955-05-13 1959-07-21 Smith Kline French Lab Sustained release pharmaceutical product
GB935672A (en) * 1960-07-19 1963-09-04 Sterling Drug Inc Sustained release tablet
DE2242844A1 (de) * 1972-08-31 1974-04-11 Wolfgang Joachim Guettner Spruehmittel auf zein-basis
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587626B2 (en) * 1985-07-29 1989-08-24 Wyeth Holdings Corporation Continuous release peptide composition
AU656897B2 (en) * 1990-07-19 1995-02-23 University Of Kentucky Research Foundation, The Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
US6777386B2 (en) 1996-08-30 2004-08-17 Peptech Limited Sustained peptide-release formulation
US7309689B2 (en) 1996-08-30 2007-12-18 Peptech Limited Sustained peptide-release formulation

Also Published As

Publication number Publication date
HUT40760A (en) 1987-02-27
DK162385A (da) 1985-10-12
DK162385D0 (da) 1985-04-10
JPS60228411A (ja) 1985-11-13
ES8607732A1 (es) 1986-06-01
PT80252B (de) 1987-02-03
GR850905B (enExample) 1985-11-25
ZA852639B (en) 1985-11-27
DE3413608A1 (de) 1985-10-24
EP0158277A3 (de) 1987-04-29
KR850007559A (ko) 1985-12-07
PT80252A (de) 1985-05-01
IL74848A0 (en) 1985-07-31
ES542045A0 (es) 1986-06-01
EP0158277A2 (de) 1985-10-16

Similar Documents

Publication Publication Date Title
AU587358B2 (en) Control of retroviruses
IL74848A0 (en) Implantable formulations of regulatory peptides with controlled release,and process for their preparation
AU2189588A (en) Artificial skin
AU4897085A (en) Intracanalicular implant
AU5295890A (en) Preparation of functional human factor viii
AU1828988A (en) Controlled release formulation
EP0282951A3 (en) Controlled release preparations of active materials
AU8317587A (en) Therapeutic preparations
AU572046B2 (en) The injection of implants into animals
PH20391A (en) Controlled release pharmaceutical preparations
AU588828B2 (en) Controlled release capsule
AU549066B2 (en) Preparation of human insulin
AU5126785A (en) Handling artificial turf
AU6287786A (en) Therapeutic composition
AU613543B2 (en) Preparation of halofluorobenzenes
AU2554884A (en) Subcutaneous implant of estradiol
AU4552389A (en) Preparation of n-acyl-aminomethylphosphonates
AU1823588A (en) Novel compounds and their preparations and formulations
AU4802285A (en) Dental implant
AU578500B2 (en) Preparation of optically active azolylcarbinols
AU3050089A (en) Cosmetic preparation
AU2317088A (en) Pacemaker system
AU566580B2 (en) Preparation of 1-azidoaldoses
AU584704B2 (en) Ocular prosthesis
AU6407686A (en) Artificial plant